KalVista Pharmaceuticals (KALV) Q4 2025 Earnings
KALV·Reported May 15, 2026·Before market open
KalVista Pharmaceuticals reported Q4 2025 revenue of $13.7M, missed analyst consensus of $39.0M by $25.3M. Diluted EPS came in at $-0.92, missed the $-0.38 consensus by $0.54.
Revenue
$13.7Mmissed by $25.3M
Consensus: $39.0MDiluted EPS
$-0.92missed by $0.54
Consensus: $-0.38
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2025 Earnings FAQ
Common questions about KalVista Pharmaceuticals's Q4 2025 earnings report.
KalVista Pharmaceuticals (KALV) reported Q4 2025 earnings on May 15, 2026 before market open.
KalVista Pharmaceuticals reported revenue of $13.7M and diluted EPS of $-0.92 for Q4 2025.
Revenue missed the consensus estimate of $39.0M by $25.3M. EPS missed the consensus estimate of $-0.38 by $0.54.